Transformation after TraumaOur lives are filled with ups and downs, triumphs and tragedies, success and stress. The question is not whether we…
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC MelanomaFebruary 28, 2023 | Source: PRINCETON, N.J.–(BUSINESS WIRE)– The applications are based on results from the Phase 3 CheckMate -76K trial,…
Functional Nutrition for Cancer SurvivorsIn this episode, we welcome Dione Detraz, RD, integrative dietitian nutritionist and author of The Cancer Diet Cookbook: Comforting Recipes…
Notes from the Lab: T-Cell Engagers, the Next Stage in Cancer Immunotherapy?By Paul Bunk, Ph.D. candidate, Cold Springs Harbor Laboratory In January 2022, tebentafusp-tebn, also known under the more easily pronounceable…
A Letter From Our Vice President | January 2023 Happy new year to you and your families! I hope that 2023 has started well for you. Before I…
TISSUE IS THE ISSUE—2023 Update on AIM’s International Melanoma Tissue Bank ConsortiumThis article is an update of an article we published last year. AIM at Melanoma’s major research initiative—the International Melanoma…
What Makes AIM’s IMTBC Even More ValuableAIM at Melanoma’s major research project, the International Melanoma Tissue Bank Consortium (IMTBC), is the first collaborative fresh frozen primary…
The Grieving Brain: The Science of Love and Loss Our guest Dr. Mary-Frances O’Connor is a renowned grief expert, author, neuroscientist, and an associate professor of psychology at…
AIM at Melanoma Earns a Four-Star Rating From Charity NavigatorDecember 21, 2022 (Richmond, California) AIM at Melanoma is proud to announce that its strong financial health and ongoing accountability…
The Future of Melanoma Treatment: 2023 and BeyondMelissa Wilson, PA-C, MPAS from UPMC Hillman Cancer Center, and Vernon Sondak, MD, Chair, Department of Cutaneous Oncology, Moffitt Cancer…
Feb. 28, 2023U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma